A Phase IB/II to Evaluate Efficacy and Safety of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 29 Mar 2019
Price : $35 *
At a glance
- Drugs Letrozole (Primary) ; SHR 6390 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 23 Mar 2019 Planned number of patients changed from 106 to 146.
- 23 Mar 2019 Planned End Date changed from 30 Dec 2020 to 30 Jun 2021.
- 15 May 2018 Status changed from not yet recruiting to recruiting.